This article is more than 5 years old. Information may no longer be current.

FDA approves Baxter's continuous renal replacement therapy solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The United States Food and Drug Administration has approved Baxter International Inc.'s Phoxillum Renal Replacement Solutions as replacement solutions in continuous renal replacement therapy. Phoxillum can be used to correct electrolyte and acid-base imbalances, and in cases of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted Phoxillum orphan drug designation for use in CRRT.

Phoxillum is a pre-mixed solution that contains phosphate, and can help treat hypophosphatemia in patients receiving continuous renal replacement therapy.

''The approval of Phoxillum allows us to offer health care providers additional options in managing critically ill acute kidney injury patients treated with CRRT,'' said Bruce Culleton, MD, vice president and renal therapeutic area lead at Baxter.

Baxter said they expect the solutionwill be available in the United States in the second quarter of 2015.